Drug Trial Radar · NCT04790513
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
Last checked: Nov 20, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Apr 22, 2021
Primary completion
Sep 30, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.
Conditions
- Hypercholesterolemia
- Cardiovascular Diseases
Interventions
lerodalcibepBiological
anti-PCSK9 small binding protein
evolocumabBiological
monoclonal antibody to PCSK9
alirocumabBiological
monoclonal antibody to PCSK9
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C reduction from baseline at 12 weeksTime frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sterling Research Group
Cincinnati, Ohio
The Lindner Research Center
Cincinnati, Ohio
Metabolic & Atherosclerosis Research Center (MARC)
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.